149 related articles for article (PubMed ID: 32002306)
1. Therapeutic melanoma vaccine with cancer stem cell phenotype represses exhaustion and maintains antigen-specific T cell stemness by up-regulating BCL6.
Czerwinska P; Rucinski M; Wlodarczyk N; Jaworska A; Grzadzielewska I; Gryska K; Galus L; Mackiewicz J; Mackiewicz A
Oncoimmunology; 2020; 9(1):1710063. PubMed ID: 32002306
[TBL] [Abstract][Full Text] [Related]
2. Whole cell melanoma vaccine genetically modified to stem cells like phenotype generates specific immune responses to ALDH1A1 and long-term survival in advanced melanoma patients.
Kwiatkowska-Borowczyk E; Czerwińska P; Mackiewicz J; Gryska K; Kazimierczak U; Tomela K; Przybyła A; Kozłowska AK; Galus Ł; Kwinta Ł; Dondajewska E; Gąbka-Buszek A; Żakowska M; Mackiewicz A
Oncoimmunology; 2018; 7(11):e1509821. PubMed ID: 30377573
[TBL] [Abstract][Full Text] [Related]
3. BNIP3L Is a New Autophagy Related Prognostic Biomarker for Melanoma Patients Treated With AGI-101H.
Kazimierczak U; Kolenda T; Kowalczyk D; Mackiewicz J; Mackiewicz A
Anticancer Res; 2020 Jul; 40(7):3723-3732. PubMed ID: 32620611
[TBL] [Abstract][Full Text] [Related]
4. Whole Cell Therapeutic Vaccine Modified With Hyper-IL6 for Combinational Treatment of Nonresected Advanced Melanoma.
Mackiewicz J; Karczewska-Dzionk A; Laciak M; Kapcinska M; Wiznerowicz M; Burzykowski T; Zakowska M; Rose-John S; Mackiewicz A
Medicine (Baltimore); 2015 May; 94(21):e853. PubMed ID: 26020391
[TBL] [Abstract][Full Text] [Related]
5. Re-induction using whole cell melanoma vaccine genetically modified to melanoma stem cells-like beyond recurrence extends long term survival of high risk resected patients - updated results.
Mackiewicz J; Burzykowski T; Iżycki D; Mackiewicz A
J Immunother Cancer; 2018 Nov; 6(1):134. PubMed ID: 30486884
[TBL] [Abstract][Full Text] [Related]
6. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
7. Changes in the TCRβ Repertoire and Tumor Immune Signature From a Cutaneous Melanoma Patient Immunized With the CSF-470 Vaccine: A Case Report.
Aris M; Bravo AI; Pampena MB; Blanco PA; Carri I; Koile D; Yankilevich P; Levy EM; Barrio MM; Mordoh J
Front Immunol; 2018; 9():955. PubMed ID: 29774030
[TBL] [Abstract][Full Text] [Related]
8. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
[TBL] [Abstract][Full Text] [Related]
9. BCL6 promotes a stem-like CD8
Sun Q; Cai D; Liu D; Zhao X; Li R; Xu W; Xie B; Gou M; Wei K; Li Y; Huang J; Chi X; Wei P; Hao J; Guo X; Pan B; Fu Y; Ni L; Dong C
Sci Immunol; 2023 Oct; 8(88):eadh1306. PubMed ID: 37862431
[TBL] [Abstract][Full Text] [Related]
10. Functional T Cell Reactivity to Melanocyte Antigens Is Lost during the Progression of Malignant Melanoma, but Is Restored by Immunization.
Przybyla A; Lehmann AA; Zhang T; Mackiewicz J; Galus Ł; Kirchenbaum GA; Mackiewicz A; Lehmann PV
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33435427
[TBL] [Abstract][Full Text] [Related]
11. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.
Walker EB; Haley D; Miller W; Floyd K; Wisner KP; Sanjuan N; Maecker H; Romero P; Hu HM; Alvord WG; Smith JW; Fox BA; Urba WJ
Clin Cancer Res; 2004 Jan; 10(2):668-80. PubMed ID: 14760090
[TBL] [Abstract][Full Text] [Related]
12. BCL6-Mediated Silencing of PD-1 Ligands in Germinal Center B Cells Maintains Follicular T Cell Population.
Peng C; Hu Q; Yang F; Zhang H; Li F; Huang C
J Immunol; 2019 Feb; 202(3):704-713. PubMed ID: 30567732
[TBL] [Abstract][Full Text] [Related]
13. Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line.
Osanto S; Schiphorst PP; Weijl NI; Dijkstra N; Van Wees A; Brouwenstein N; Vaessen N; Van Krieken JH; Hermans J; Cleton FJ; Schrier PI
Hum Gene Ther; 2000 Mar; 11(5):739-50. PubMed ID: 10757353
[TBL] [Abstract][Full Text] [Related]
14. Bcl6 acts as an amplifier for the generation and proliferative capacity of central memory CD8+ T cells.
Ichii H; Sakamoto A; Kuroda Y; Tokuhisa T
J Immunol; 2004 Jul; 173(2):883-91. PubMed ID: 15240675
[TBL] [Abstract][Full Text] [Related]
15. Bcl6 drives stem-like memory macrophages differentiation to foster tumor progression.
Zhang W; Han Q; Ding Y; Zhou H; Chen Z; Wang J; Xiang J; Song Z; Abbas M; Shi L
Cell Mol Life Sci; 2022 Dec; 80(1):14. PubMed ID: 36542153
[TBL] [Abstract][Full Text] [Related]
16. Dissecting the Immune Stimulation Promoted by CSF-470 Vaccine Plus Adjuvants in Cutaneous Melanoma Patients: Long Term Antitumor Immunity and Short Term Release of Acute Inflammatory Reactants.
Pampena MB; Cartar HC; Cueto GR; Levy EM; Blanco PA; Barrio MM; Mordoh J
Front Immunol; 2018; 9():2531. PubMed ID: 30450100
[TBL] [Abstract][Full Text] [Related]
17. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.
Grover A; Kim GJ; Lizée G; Tschoi M; Wang G; Wunderlich JR; Rosenberg SA; Hwang ST; Hwu P
Clin Cancer Res; 2006 Oct; 12(19):5801-8. PubMed ID: 17020987
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the class I-restricted gp100 melanoma peptide-stimulated primary immune response in tumor-free vaccine-draining lymph nodes and peripheral blood.
Walker EB; Miller W; Haley D; Floyd K; Curti B; Urba WJ
Clin Cancer Res; 2009 Apr; 15(7):2541-51. PubMed ID: 19318471
[TBL] [Abstract][Full Text] [Related]
19. Bcl6 is essential for the generation of long-term memory CD4+ T cells.
Ichii H; Sakamoto A; Arima M; Hatano M; Kuroda Y; Tokuhisa T
Int Immunol; 2007 Apr; 19(4):427-33. PubMed ID: 17307796
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination.
Powell DJ; Rosenberg SA
J Immunother; 2004; 27(1):36-47. PubMed ID: 14676632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
